322 related articles for article (PubMed ID: 26975494)
1. DNA alterations in the tumor genome and their associations with clinical outcome in prostate cancer.
Liu W
Asian J Androl; 2016; 18(4):533-42. PubMed ID: 26975494
[TBL] [Abstract][Full Text] [Related]
2. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.
Beltran H; Yelensky R; Frampton GM; Park K; Downing SR; MacDonald TY; Jarosz M; Lipson D; Tagawa ST; Nanus DM; Stephens PJ; Mosquera JM; Cronin MT; Rubin MA
Eur Urol; 2013 May; 63(5):920-6. PubMed ID: 22981675
[TBL] [Abstract][Full Text] [Related]
3. The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies.
Berg KD
Dan Med J; 2016 Dec; 63(12):. PubMed ID: 27910803
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in prostate cancer research: large-scale genomic analyses reveal novel driver mutations and DNA repair defects.
Frank S; Nelson P; Vasioukhin V
F1000Res; 2018; 7():. PubMed ID: 30135717
[TBL] [Abstract][Full Text] [Related]
5. Predisposition for TMPRSS2-ERG fusion in prostate cancer by variants in DNA repair genes.
Luedeke M; Linnert CM; Hofer MD; Surowy HM; Rinckleb AE; Hoegel J; Kuefer R; Rubin MA; Vogel W; Maier C
Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):3030-5. PubMed ID: 19861517
[TBL] [Abstract][Full Text] [Related]
6. Spatial Intratumor Genomic Heterogeneity within Localized Prostate Cancer Revealed by Single-nucleus Sequencing.
Su F; Zhang W; Zhang D; Zhang Y; Pang C; Huang Y; Wang M; Cui L; He L; Zhang J; Zou L; Zhang J; Li W; Li L; Shao J; Ma J; Xiao F; Liu M
Eur Urol; 2018 Nov; 74(5):551-559. PubMed ID: 29941308
[TBL] [Abstract][Full Text] [Related]
7. Genetic markers associated with early cancer-specific mortality following prostatectomy.
Liu W; Xie CC; Thomas CY; Kim ST; Lindberg J; Egevad L; Wang Z; Zhang Z; Sun J; Sun J; Koty PP; Kader AK; Cramer SD; Bova GS; Zheng SL; Grönberg H; Isaacs WB; Xu J
Cancer; 2013 Jul; 119(13):2405-12. PubMed ID: 23609948
[TBL] [Abstract][Full Text] [Related]
8. Expression of DNA ligase IV is linked to poor prognosis and characterizes a subset of prostate cancers harboring TMPRSS2:ERG fusion and PTEN deletion.
Grupp K; Roettger L; Kluth M; Hube-Magg C; Simon R; Lebok P; Minner S; Tsourlakis MC; Koop C; Graefen M; Adam M; Haese A; Wittmer C; Sauter G; Wilczak W; Huland H; Schlomm T; Steurer S; Krech T
Oncol Rep; 2015 Sep; 34(3):1211-20. PubMed ID: 26134445
[TBL] [Abstract][Full Text] [Related]
9. Distinct Genomic Alterations in Prostate Tumors Derived from African American Men.
Liu W; Zheng SL; Na R; Wei L; Sun J; Gallagher J; Wei J; Resurreccion WK; Ernst S; Sfanos KS; Isaacs WB; Xu J
Mol Cancer Res; 2020 Dec; 18(12):1815-1824. PubMed ID: 33115829
[TBL] [Abstract][Full Text] [Related]
10. Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate Cancer.
Hubbard GK; Mutton LN; Khalili M; McMullin RP; Hicks JL; Bianchi-Frias D; Horn LA; Kulac I; Moubarek MS; Nelson PS; Yegnasubramanian S; De Marzo AM; Bieberich CJ
Cancer Res; 2016 Jan; 76(2):283-92. PubMed ID: 26554830
[TBL] [Abstract][Full Text] [Related]
11. Combined analysis of TMPRSS2-ERG and TERT for improved prognosis of biochemical recurrence in prostate cancer.
Sabaliauskaite R; Jarmalaite S; Petroska D; Dasevicius D; Laurinavicius A; Jankevicius F; Lazutka JR
Genes Chromosomes Cancer; 2012 Aug; 51(8):781-91. PubMed ID: 22505341
[TBL] [Abstract][Full Text] [Related]
12. Genomic analysis of Korean patients with advanced prostate cancer by use of a comprehensive next-generation sequencing panel and low-coverage, whole-genome sequencing.
Kang M; Cho E; Jang J; Lee J; Jeon Y; Jeong BC; Seo SI; Jeon SS; Lee HM; Choi HY; Jeon HG
Investig Clin Urol; 2019 Jul; 60(4):227-234. PubMed ID: 31294131
[TBL] [Abstract][Full Text] [Related]
13. Identification of Combinatorial Genomic Abnormalities Associated with Prostate Cancer Early Recurrence.
Qu X; Jeldres C; Glaskova L; Friedman C; Schroeder S; Nelson PS; Porter C; Fang M
J Mol Diagn; 2016 Mar; 18(2):215-24. PubMed ID: 26752304
[TBL] [Abstract][Full Text] [Related]
14. Abnormal expression of the ERG transcription factor in prostate cancer cells activates osteopontin.
Flajollet S; Tian TV; Flourens A; Tomavo N; Villers A; Bonnelye E; Aubert S; Leroy X; Duterque-Coquillaud M
Mol Cancer Res; 2011 Jul; 9(7):914-24. PubMed ID: 21669963
[TBL] [Abstract][Full Text] [Related]
15. Functional deficiency of DNA repair gene EXO5 results in androgen-induced genomic instability and prostate tumorigenesis.
Ali S; Zhang Y; Zhou M; Li H; Jin W; Zheng L; Yu X; Stark JM; Weitzel JN; Shen B
Oncogene; 2020 Feb; 39(6):1246-1259. PubMed ID: 31616062
[TBL] [Abstract][Full Text] [Related]
16. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
[TBL] [Abstract][Full Text] [Related]
17. High alpha-methylacyl-CoA racemase (AMACR) is associated with ERG expression and with adverse clinical outcome in patients with localized prostate cancer.
Box A; Alshalalfa M; Hegazy SA; Donnelly B; Bismar TA
Tumour Biol; 2016 Sep; 37(9):12287-12299. PubMed ID: 27271990
[TBL] [Abstract][Full Text] [Related]
18. Nuclear C-MYC expression level is associated with disease progression and potentially predictive of two year overall survival in prostate cancer.
Zeng W; Sun H; Meng F; Liu Z; Xiong J; Zhou S; Li F; Hu J; Hu Z; Liu Z
Int J Clin Exp Pathol; 2015; 8(2):1878-88. PubMed ID: 25973080
[TBL] [Abstract][Full Text] [Related]
19. Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis.
Robert G; Jannink S; Smit F; Aalders T; Hessels D; Cremers R; Mulders PF; Schalken JA
Prostate; 2013 Jan; 73(2):113-20. PubMed ID: 22674214
[TBL] [Abstract][Full Text] [Related]
20. TMPRSS2-ERG status is not prognostic following prostate cancer radiotherapy: implications for fusion status and DSB repair.
Dal Pra A; Lalonde E; Sykes J; Warde F; Ishkanian A; Meng A; Maloff C; Srigley J; Joshua AM; Petrovics G; van der Kwast T; Evans A; Milosevic M; Saad F; Collins C; Squire J; Lam W; Bismar TA; Boutros PC; Bristow RG
Clin Cancer Res; 2013 Sep; 19(18):5202-9. PubMed ID: 23918607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
